---
title: "Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292619451.md"
description: "Plus Therapeutics highlights updated NCCN CNS Cancers Guidelines, which emphasize cerebrospinal fluid (CSF) analysis for diagnosing and managing leptomeningeal metastases. The guidelines recommend regular CSF cytology follow-ups every 4 to 8 weeks during intrathecal therapy to monitor treatment efficacy and disease progression. This reinforces the clinical role of Plus Therapeutics' CNSide® in optimizing patient outcomes through comprehensive longitudinal monitoring."
datetime: "2026-07-14T11:31:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292619451.md)
  - [en](https://longbridge.com/en/news/292619451.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292619451.md)
---

# Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Revised NCCN guidelines emphasize the importance of cerebrospinal fluid (CSF) analysis for diagnosing and managing leptomeningeal metastases. It recommends regular CSF cytology follow-ups every 4 to 8 weeks for patients undergoing intrathecal therapy. This approach aids in the ongoing monitoring of patients' conditions, ensuring comprehensive care. The updated guidelines reinforce the significance of CSF analysis in the clinical management of leptomeningeal metastases, underscoring the need for regular follow-ups to assess treatment efficacy and disease progression. These recommendations aim to optimize patient outcomes and enhance longitudinal monitoring of individuals with this condition.

### Related Stocks

- [PSTV.US](https://longbridge.com/en/quote/PSTV.US.md)

## Related News & Research

- [Plus Therapeutics flags availability of CNS cancers guidelines update release](https://longbridge.com/en/news/292616746.md)
- [A New CNS Cancer Treatment Playbook In The Making?](https://longbridge.com/en/news/293224007.md)
- [Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey | ELV Stock News](https://longbridge.com/en/news/294391678.md)
- [Veracyte Q2 revenue rises on Decipher and Afirma test sales](https://longbridge.com/en/news/294410825.md)
- [YD Bio launches cancer testing pilot with Numia Health in Canada](https://longbridge.com/en/news/294062286.md)